

AstraZeneca
2013 Full Year Results



Cautionary statement regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This presentation contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted.

The forward-looking statements reflect knowledge and information available at the date of preparation of this presentation and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation.

Nothing in this presentation should be construed as a profit forecast.

Agenda

Pascal Soriot
2013: Gaining momentum

Marc Dunoyer
2013 financial performance and 2014 guidance

Briggs Morrison
Pipeline review

Pascal Soriot
Closing remarks

2013: Gaining momentum

Pascal Soriot
Chief Executive Officer, AstraZeneca

2013 was an important step on our journey



2013 financial results in line with our expectations

Revenue	**$25,711m**	-6% (CER)
Core EPS	**$5.05**	-23% (CER)
Dividend per share	**$2.80**	

2013 global revenues in line with our expectations

	2013 $m	CER growth
Global Revenue	**25,711**	**-6%**
US	9,691	-9%
Europe	6,658	-9%
Emerging Markets	5,389	+8%
Japan	2,485	+4%
Other established ROW	1,488	-29%

Good progress in 2013 across our strategic priorities

1 Achieve scientific leadership

2 Return to growth

3 Be a great place to work

Late stage pipeline almost doubled and core TAs strengthened

1

Achieve scientific leadership

6 additions to late stage pipeline

- Oncology: Olaparib, selumetinib, moxetumomab
- RIA: Benralizumab, PT003
- CVMD: Epanova

Strengthened oncology and other core TAs

- Immunocore, Spirogen, Amplimmune, Fibrogen, Pearl, Moderna, BMS Diabetes Acquisition

R&D model transformation accelerated

- UK and US changes accelerated, biotech model implemented

Good progress in 2013 across our strategic priorities

1

Achieve scientific leadership

2

Return to growth

3

Be a great place to work

Growth platform revenues up 10% to $12.5bn

	2013 $m	CER growth %
Growth drivers	**12,471**	**10**
Brilinta	283	216
Diabetes	787	75
Respiratory	4,677	7
Emerging Markets	5,389	8
Japan	2,485	4

Brilinta: Good progress Europe, International



- 2013 *Brilinta* revenues up **216%** to **$283m**
- Leadership position achieved in some European markets
- Making progress but more work needed in the US

Note: Growth rates all CER

Brilinta: US performance



Brilinta: Investing to realise significant potential

Large untapped volume with active clinical trials to access opportunity



- **Today:** Investments made in *Brilinta* promotion, access, affordability, scientific leadership
- **2014:** Commercial focus sharpened across US, EU and International geographies
- **2016:** Significant value creation potential through LCM programs in post-MI (PEGASUS), acute stroke (SOCRATES) & PAD (EUCLID)

Source: IMS Health. Copyright 2014. All rights reserved. MIDAS; Kantar Health Epi Database; Millennium Research Group; AstraZeneca Global Forecasting Analysis.
Note: OAP volume is based on days of therapy. Note: This slide is necessarily forward looking and includes areas for which additional studies may be explored for the purpose of seeking additional indications or expanded labelling

Diabetes: building the franchise



- Revenues growing to **$787m**
- Diabetes acquisition closed 1 February
- Onglyza stable
- Exenatide share growing
- Farxiga US launch 7 February

Note: Growth rates all CER

Diabetes: BYDUREON gaining TRx & NBRx share in US

Exit Share Gains	Q1	Q2	Q3	Q4	FY
TRx	+2.0	+0.8	+0.8	+0.9	+4.5
NBRx	-0.9	-2.1	+1.9	+0.9	-0.2



Respiratory: Symbicort up 10%



- 2013 Symbicort revenues up **10%** to **$3,483m**
- Symbicort NBRx market share was up **7 points** in US
- Share growth in Japan, China and many International markets

Note: Growth rates all CER

Respiratory: US SYMBICORT Net Sales +23%



Emerging Markets: Up 8%, driven by China

AZ significantly outgrows MNC and total market in China

Japan: strong in-market growth

Good performance

- AZKK up from 12th to 9th in ranking
- Growth +4% CER
- In-market growth +11%

Source: IMS Health. Copyright 2014. All rights reserved.

Growth in brand volume market share (points)



Source: IMS Health. Copyright 2014. All rights reserved. Points show 2013 vs. 2012



AstraZeneca
2013 Full Year Results



2013 financial performance and 2014 guidance

Marc Dunoyer,
Chief Financial Officer

Headline results 2013

	Q4 2013	Q4 2012	CER	FY 2013	FY 2012	CER
Revenue	6,844	7,282	-4%	25,711	27,973	-6%
Core Operating Profit	1,983	2,795	-26%	8,390	11,159	-22%
Core EPS	$1.23	$1.71	-25%	$5.05	$6.83	-23%

Core margin FY 2013

	$m	CER growth	% sales	Delta vs PY CER
Revenue	**25,711**	**-6%**		
Core Gross Margin	21,078	-7%	82.0	-50bps
Distribution	(306)	-3%	1.2	0bps
Core R&D	(4,269)	+1%	16.6	-110bps
Core SG&A	(8,865)	+7%	34.5	-430bps
Core Other Income	752	-30%	2.9	-100bps
Core Operating Profit	**8,390**	**-22%**	**32.6**	**-690bps**

Restructuring update

	March 2013	Additional activities	Feb 2014
COSTS	**$2.3bn**	**+$0.9bn**	**$3.2bn**
CASH	**$1.7bn**	**+$0.7bn**	**$2.4bn**
ANNUAL BENEFITS ON COMPLETION (2016)	**$0.8bn**	**+$0.3bn**	**$1.1bn**
HEADCOUNT (Gross FTEs)	**(5,050)**	**(550)**	**(5,600)**

Cash generation: FY 2013

	2013 $m	2012 $m
EBITDA	8,295	10,666
Movement in working capital	166	(706)
Tax & interest paid	(1,319)	(2,588)
Other non-cash movements	258	(424)
Net cash from operating activities	**7,400**	**6,948**

Cash application: FY 2013

	2013 $m
Net cash from operating activities	7,400
Net capex	(673)
Dividends/share issues	(2,979)
Acquisitions and business development	(2,273)
Other movements	(11)
Net cash flow after distributions	**1,464**

Business development aligned with priority TAs



Cash distributions

Dividend	• FY 2013 dividend $2.80 per share
Share repurchases	• FY 2013: No share repurchases • FY 2014: No repurchases planned currently

Guidance

2014 Revenue (CER)	Low-to-mid single digit decline
2014 Core EPS (CER)	Percentage decline in the teens
Dividend	Progressive dividend policy reconfirmed

Above guidance assumes US *Nexium* generic end of May 2014

2017 Revenue (CER)	Broadly in line with 2013



AstraZeneca
2013 Full Year Results



Pipeline review

Briggs Morrison, Executive Vice President
Global Medicines Development

Pipeline review

2013	Significant phase III & pipeline progression
2014	Exciting assets underpinning scientific leadership

We anticipated 5-7 NME Phase 3 starts 2013-2014

2013	2014	
benralizumab asthma ✓	**AZD6765** depression	**ATM AVI** serious infections
olaparib solid tumours ✓	**sifalimumab/MEDI-546** systemic lupus erythematosus	**AZD4547** gastric cancer
moxetumomab pasudotox hairy cell leukaemia ✓	**mavrilimumab** rheumatoid arthritis	**AZD5069** asthma
selumetinib non-small cell lung cancer ✓	**MEDI-551** haematological malignancies	**tralokinumab** asthma

Terminated **2015**

Continuous news flow in 2013 as anticipated

	Product	Milestone	
NME	fostamatinib – rheumatoid arthritis	Phase III data	✗
	naloxegol – opioid-induced constipation	Phase III data (KODIAC-08)	✓
	moxetumomab pasudotox – hairy cell leukaemia	Potential phase III start	✓
	olaparib – solid tumours	Potential phase III start	✓
	CXL – methicillin-resistant Staphylococcus aureus	Potential phase III start	✗
	benralizumab – asthma	Potential phase III start	✓
	selumetinib – non-small cell lung cancer	Potential phase III start	✓
	naloxegol – opioid-induced constipation	Submission for approval in USA & Europe	✓
	fostamatinib – rheumatoid arthritis	Submission for approval in USA & Europe	✗
OTHER	Forxiga – type 2 diabetes (triple therapy)	Submission for approval in Europe	✓
	Brilinta – acute coronary syndrome	Submission for approval in Japan	✓
	Forxiga – type 2 diabetes	Submission for approval in Japan & China	✓
	Zoladex – three month depot (breast cancer)	Submission for approval in Japan	✓
	Onglyza SAVOR-TIMI53 – outcomes study	Study results	✓
	brodalumab – psoriatic arthritis	Potential phase III start	2014
	Forxiga – type 2 diabetes	Resubmission for approval in USA	✓
	Onglyza SAVOR-TIMI53 – outcomes study	Submission for approval in USA &Europe	✓
	Bydureon Dual Chamber Pen – type 2 diabetes	Submission for approval in USA	✓
	FluMist Quadrivalent – flu vaccine	Launch in US	✓
	Casodex oral dispersible tablet	Launch in Japan	✓

2013 pipeline delivery

Regulatory approvals

- Farxiga (US)
- Xigduo (dapagliflozin+metformin) (EU)
- Fluenz Tetra (EU)

Regulatory submissions

- Epanova (US)
- Metreleptin (US)
- Olaparib (EU)
- Naloxegol (US & EU)
- Bydureon dual chamber pen (US & EU)

Phase III starts

- Olaparib in BRCAm Ovarian Cancer
- Moxetumomab in hairy cell leukaemia
- Benralizumab in severe asthma
- Selumetinib in 2nd line KRASm NSCLC

Pipeline progression

- AZD9291 Phase I data
- MEDI4736 (PD-L1) Phase I data
- MEDI0680 (PD-1) first dose in human
- Multiple IMT-C combination trials initiated

Faster than anticipated pipeline progression & re-deployed R&D spend toward late development

Target of 10 potential NMEs in Phase 3 pipeline by 2016 achieved already in 2013



Pipeline progression driving shift toward late development



A growing and accelerating late stage pipeline

Phase 1
33 New Molecular Entities

Small molecule

- **AZD5363** AKT solid tumours
- **AZD6094 (volitinib)** MET solid tumours
- **AZD1208** PIM haems
- **AZD9150** STAT3 haems + solids
- **AZD9291** EGFRm+ solid tumours
- **AZD8186** PI3Kβδ solid tumours
- **AZD6738** ATR CLL/H&N
- **AZD8848** Inhaled TLR7 agonist asthma
- **AZD7624** Inhaled p38 inhibitor COPD
- **AZD4721** CXCR2 COPD
- **AZD1419** TLR9 asthma
- **PT010** LABA/LAMA/ICS COPD
- **AZD3293** BSECDR Alzheimer's
- **AZD6423** NMDA suicidal ideation
- **ATM AVI** BL/BLI SBI
- **AZD0914** GHyrAR serious infection

Large molecule

- **MEDI0639** DLL-4 solid tumours
- **MEDI-565** CEA BiTE GI tumours
- **MEDI3617** ANG-2 solid tumours
- **MEDI6469** mOx40 solid tumours
- **MEDI0680** PD-1 solid tumours
- **MEDI4736** PD-L1 solid tumours
- **MEDI4736+tremelimumab** PD-L1+CTLA-4 solid tumours
- **MEDI4736+dabraf+trametinib** PD-L1+BRAF+MEK melanoma
- **moxetumomab CD22, pALL**
- **MEDI5872** B7RP1 SLE
- **MEDI9929** TSLP asthma
- **MEDI-551** CD19 MS
- **MEDI6012** LCAT, ACS
- **MEDI4893** staph alpha toxin SSI
- **MEDI-559 (PRVV)** RSV prophylaxis
- **MEDI-550** Panflu library
- **MEDI9287** H7N9 avian influenza

Phase 2
27 New Molecular Entities

Small molecule

- **AZD4547** FGFR solid tumours
- **AZD1775** Wee-1 ovarian
- **AZD2014** TORK solid tumours
- **olaparib** PARP breast
- **selumetinib** MEK haems + solids
- **AZD5069** CXCR2 antagonist asthma
- **AZD2115** MABA (dual) COPD
- **RDEA3170** URAT1 - gout
- **AZD4901** Hormone modulator PCOS
- **AZD1722** NHE3 inhibitor ESRD/CKD
- **roxadustat (AZD9941)** HIF anaemia CKD/ESRD
- **AZD3241** MPO Parkinson's Disease
- **AZD5213** H3R Tourette's/neuropathic pain
- **AZD5847** oxazolidinone TB
- **CXL** BLI/cephalosporin MRSA

Large molecule

- **MEDI-573** IGF MBC
- **MEDI-551** CD19 CLL, DLBCL
- **tremelimumab** CTLA-4 mesothelioma
- **sifalimumab (SLE)** IFNa SLE
- **MEDI8968** IL-1R COPD, HS
- **mavrilimumab** GM-CSFR RA
- **MEDI7183** α4β7 UC, Crohn's
- **tralokinumab** IL-13 asthma, IPF
- **MEDI2070** IL-23 Crohn's
- **MEDI-546** IFNaR SLE
- **benralizumab** IL-5R COPD
- **brodalumab** IL-17R asthma/psoriatic arthritis

Phase 3
11 New Molecular Entities

Small molecule

- **selumetinib** MEK 2L KRAS NSCLC
- **Olaparib** PARP BRCA ovarian, gastric
- **lesinurad** URAT1 gout
- **PT003** LABA/LAMA COPD
- **Epanova** hypertriglyceridaemia
- **naloxegol** opioid induced constipation
- **CAZ AVI** BLI/cephalosporin SBI

Large molecule

- **moxetumomab** CD22, HCL
- **brodalumab** IL-17R psoriasis
- **benralizumab** IL-5R asthma
- **metreleptin** lipodystrophy

Oncology | RIA | CVMD | Neuroscience | Infection

19 candidates for NME registration trial starts in 2014-15

2014	2015	
AZD9291 NSCLC	**AZD4547** gastric cancer	**ATM AVI** serious infections
MEDI4736 solid tumours	**MEDI-573** metastatic breast cancer	**RDEA 3170** gout
tralokinumab asthma	**MEDI-551** CLL	**sifalimumab/MEDI-546** systemic lupus erythematosus
roxadustat (FG4592) ESRD/CKD	**volitinib (AZD6094)** papillary renal cell carcinoma	**Pearl Triple PT010** COPD
AZD3293 Alzheimer's	**AZD1775** ovarian cancer	**AZD5069** asthma
mavrilimumab rheumatoid arthritis	**MEDI3617** ovarian cancer	**AZD1722** ESRD
	AZD9150 DLBCL	

Potential NME registration trial starts in 2014

2014
AZD9291 NSCLC
MEDI4736 solid tumours
tralokinumab asthma
roxadustat (FG4592) ESRD/CKD
AZD3293 Alzheimer's
mavrilimumab rheumatoid arthritis

We anticipate 4-5 NME registration trials

MEDI4736 (anti-PD-L1)

Empowering the Immune System to Fight Cancer

Novel approach, supporting multiple combination opportunities

- Validated pathway
- Strong scientific rationale for combinations
- Phase I dose-escalation/expansion monotherapy in solid tumours & combination trials ongoing, data at ASCO and ESMO
- Monotherapy phase III start anticipated in 2014
- PYS potential >$1bn

Encouraging level of clinical activity in Phase I dose-escalation[1]



[1] Khleif S, et al. Data presented at an oral session at ECCO/ESMO conference, Amsterdam, Netherlands, 27 Sep - 1 Oct 2013

AZD9291 (3rd generation EGFR-TKI)

A novel small molecule targeting key genetic segment in NSCLC

Leading the way in area of high unmet medical need

- Oral irreversible inhibitor of both EGFR sensitising and EGFR T790M resistance mutations
- Phase I dose-escalation & cohort expansion in EGFR T790M mutant NSCLC ongoing, further data at ASCO
- Anticipated to enter Phase III in 2014
- PYS potential >$1bn

Encouraging evidence of monotherapy activity[1]

Best % change from baseline in target lesions, n=34



Best overall response#

- 15/35 patients evaluated had a partial response (confirmed + unconfirmed)
- 9/18 patients with T790M+ tumours achieved a partial response (confirmed + unconfirmed)

#Response Evaluation Criteria in Solid Tumors v1.1, programmatically calculated from investigator-recorded tumour measurements
T790M result from local testing except for some expansion patients where local testing result unknown (central test result used)

Preliminary data, cut-off 27 September 2013

[1] Ransom M, et al. Data presented at a mini-oral session at the 15th World Conference of Lung Cancer, Sydney, Australia, 27-30 October 2013

Roxadustat/FG4592

Anaemia treatment beyond the boundaries of current ESA therapy

First in Class oral HIF-PHD inhibitor for CKD & ESRD

- Potential first HIF-PHD inhibitor with filing in 2016 (China) and 2018 (US)
- Potential use in Anaemia of Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD)
- High unmet need for oral agent with improved safety profile
- Anticipated to enter Phase III in 2014
- PYS Potential >$1bn

Stimulates EPO production without need for concomitant iron treatment



AZD3293 (BACE1 inhibitor)

Highly potent inhibitor of the first step in Aβ peptide production

Highly promising approach to address unmet medical need in Alzheimer's

- Alzheimer's disease pathology is characterised by Aβ peptide deposition
- Disease causing mutations in APP directly linked to BACE activity
- Potential to slow disease progression in prodromal and mild Alzheimer's disease
- Anticipated registrational trial start in 2014
- PYS potential >$1bn

AZD3293 has demonstrated significant dose dependent reduction in CSF Aβ in Phase 1[1]



[1] Budd H. S. et al (2013) AZD3293 a novel BACE1 inhibitor: Effect on plasma and CSF Abeta peptides following single and multiple-dose administration. Journal of Nutrition, Health and Aging Issue 9, Vol 17

Potential NME and LCM submissions 2014-2016



Key:

- Oncology
- RIA
- CVMD
- Infection



AstraZeneca
2013 Full Year Results



Closing remarks

Pascal Soriot
Chief Executive Officer, AstraZeneca

Carrying momentum into 2014

Q1

Farxiga, Type 2 Diabetes
FDA Approval ✓

Dapagliflozin, Type 2 Diabetes
Potential Approval Japan

Olaparib, Ovarian Cancer Platinum Relapsed
US Submission

Xigduo, Type 2 Diabetes
EU Approval ✓

Naloxegol, Opioid Induced Constipation
US Ad Comm, postponed

Q2

Epanova, Severe Hypertriglyceridaemia
PDUFA, May 5

Benralizumab, Tralokinumab
ATS P2 Results Presentations

Analyst Meeting
ATS, May 16 – 21

Medi 4736, Olaparib, AZD 9291
ASCO Results Presentations

Analyst Meeting
ASCO, May 30 – June 3

Saxagliptin/Dapagliflozin, Type 2 Diabetes
Data In Combined Usage

Bydureon Dual Chamber Pen, Type 2 Diabetes
Potential FDA Approval

Q3

Iressa, NSCLC
Submission US

Olaparib, Ovarian Cancer Platinum Relapsed
Potential US Approval

CAZ-AVI, Complicated Intra-Abdominal Infections
P3 Results

Immuno-oncology monotherapy
ESMO Results Presentations

Naloxegol, Opioid Induced Constipation
PDUFA, September 16

Q4

PT-003, COPD
P3 Results

Brodalumab, Psoriasis
P3 Results

Olaparib, Ovarian Cancer Platinum Relapsed
Potential EU Approval

Dapagliflozin+saxagliptin FDC, Type 2 Diabetes
FDA Submission

Xigduo XR FDC, Type 2 Diabetes
Potential FDA Approval

Lesinurad, Gout
P3 Results (ACR) and Submission EU & US

Bydureon Dual Chamber Pen, Type 2 Diabetes
Potential EU Approval

Ruud Dobber,
EVP, Europe & EVP Global Portfolio & Product Strategy (interim)

Bahija Jallal,
EVP, MedImmune

Mene Pangalos,
EVP, Innovative Medicines & Early Development



AstraZeneca
2013 Full Year Results